EurOPDX members from VHIO publish promising data for a potential new & safe treatment of HER2+ breast cancer

EurOPDX Consortium partners at the Vall d’Hebron Institute of Oncology (VHIO) in Barcelona, Spain, in collaboration with the Roche Innovation Center Zurich and other academic institutions, have developed a novel T-cell bispecific antibody with a potent anti-tumour effect for breast cancer treatment.

Described in a recent publication in the journal Science Translation Medicine and led by Joaquín Arribas, findings show that a newly developed p95HER2-T cell bispecific antibody (p9HER2-TCB) showed strong anti-tumour effects. This antibody includes, within a single entity, a T-cell receptor binding site to boost immune response to the tumour, and a binding site to a fragment of the HER2 tumour-associated antigen, known as p95HER2 (present in ~10% of breast cancers). By focussing on this tumour-specific antigen, since p95HER2 is not expressed in non-tumour tissues, the researchers treatment will be able to avoid the severe toxicities associated with current therapies targeting HER2, which is also expressed in normal epithelial cells. Thus, the data presented suggest the potential for a new, safe, treatment for the HER2-positive subset of breast cancers.

Find the full publication here: